SabinaGuffey: revised

2026-03-14T21:34:42Z

revised

UpdateBot: robot: Update article (please report if you notice any mistake or error in this edit)

2022-06-12T02:13:32Z

robot: Update article (please report if you notice any mistake or error in this edit)

← Older revision		Revision as of 07:43, 12 June 2022
Line 1:		Line 1:
			{{Use dmy dates\|date=June 2022}}
			{{Use Indian English\|date=June 2022}}
	{{Infobox company		{{Infobox company
	\| name = Natco Pharma		\| name = Natco Pharma
Line 4:		Line 6:
	\| logo_size =		\| logo_size =
	\| caption =		\| caption =
	\| type = Public company		\| type = [[Public company\|Public]]
	\| genre =		\| genre =
	\| traded_as = {{NSE\|NATCOPHARM}} <br /> {{BSE\|524816}}		\| traded_as = {{NSE\|NATCOPHARM}} <br /> {{BSE\|524816}}
Line 10:		Line 12:
	\| successor =		\| successor =
	\| foundation = 1981		\| foundation = 1981
	\| ~~founders~~ = VC Nannapaneni		\| founder = VC Nannapaneni
	\| defunct =		\| defunct =
	\| location_city = [[Hyderabad]]		\| location_city = [[Hyderabad]], [[Telangana]]
	\| location_country = [[India]]		\| location_country = India
	\| locations =		\| locations =
	\| area_served = Global		\| area_served = Global
Line 20:		Line 22:
	\| products =		\| products =
	\| services =		\| services =
	\| revenue =		\| revenue = {{INRconvert\|2155\|c}} (FY2021)
	\| operating_income =		\| operating_income =
	\| net_income =		\| net_income =
Line 27:		Line 29:
	\| equity =		\| equity =
	\| owner =		\| owner =
	\| num_employees =		\| num_employees =
	\| parent =		\| parent =
	\| divisions =		\| divisions =
Line 33:		Line 35:
	\| footnotes =		\| footnotes =
	}}		}}
			'''Natco Pharma''' is an Indian multinational [[pharmaceutical]] company based in [[Hyderabad]]. The company manufactures finished dosage formulations [[active pharmaceutical ingredients]] and [[Agricultural science\|crop health science]] products, and also provides [[Contract manufacturing organization\|contract manufacturing services]].<ref name=":0">{{Cite web \|title=Our Business {{!}} Natco Pharma \|url=https://www.natcopharma.co.in/our-business/ \|access-date=2022-04-25}}</ref> It is a major producer of branded [[oncology]] medicines<ref name="paraiv">{{cite news \|title=Natco Pharma lines up 20 'Para IV' products \|url=https://www.thehindubusinessline.com/companies/natco-pharma-lines-up-20-para-iv-products/article29408594.ece \|accessdate=19 April 2020 \|work=The Hindu Business Line}}</ref> and [[hepatitis C]] drugs.<ref name=ladder/> The company specialises in producing complex medicines at affordable prices.<ref>{{Cite news \|last=PTI \|date=17 December 2020 \|title=Natco Pharma launches anti blood clot medication, Rivaroxaban, in India \|work=The Economic Times \|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-anti-blood-clot-medication-rivaroxaban-in-india/articleshow/79779503.cms?from=mdr \|access-date=2022-04-25}}</ref><ref>{{Cite web \|last=Akolkar \|first=Shrikant \|date=9 March 2017 \|title=Natco Pharma: Top league player \|url=https://www.angelone.in/get-co-pdf/AngelBrokingResearch_NatcoPharma_Inititatingcoverage_090317.pdf \|access-date=25 April 2022 \|website=Angel One}}</ref> In 2019, Natco launched its crop health sciences division.<ref>{{Cite web \|title=Mission & Heritage {{!}} Natco Pharma \|url=https://www.natcopharma.co.in/about/mission-heritage/ \|access-date=2022-04-25}}</ref><ref>{{Cite web \|last=Sridhar \|first=G. Naga \|date=2020-11-25 \|title=Natco Pharma expects agri business to be key growth lever \|url=https://www.thehindubusinessline.com/companies/natco-pharma-expects-agri-business-to-be-key-growth-lever/article33175348.ece \|access-date=2022-04-24 \|website=www.thehindubusinessline.com \|language=en}}</ref>

	~~'''~~Natco Pharma'~~'' is an Indian~~ [[~~pharmaceutical~~]] ~~company~~ based in [[~~Hyderabad~~]]~~, which makes finished dosage formulations~~ and [[~~active pharmaceutical ingredients~~]]~~. It is the market leader in branded~~ [[~~oncology~~]] ~~medicines in India,~~<ref name=~~paraiv~~>{{cite news \|title=Natco ~~Pharma lines~~ up ~~20 `Para IV~~' ~~products~~ \|url=https://www.~~thehindubusinessline~~.com/companies/natco-~~pharma~~-~~lines~~-up-20-~~para~~-iv-~~products/article29408594~~.~~ece~~ \|accessdate=19 April 2020 \|work=~~The Hindu Business Line~~}}</ref> and ~~among the country's top three producers of~~ [[hepatitis C]] drugs.<ref name=~~ladder~~/>		== History ==
			* In 2003, Natco Pharma launched Veenat, a generic version of [[Novartis AG]]'s anti-cancer drug [[Glivec]]. It won the subsequent patent protection legal battle against Novartis in 2013.<ref name="niche">{{cite news\|title=Niche Play\|work=Business Today\|url=https://www.businesstoday.in/story/vc-nannapaneni-natco-pharma-ceo-best-ceo-business-today-survey-pharmaceutical-industry-hyderabad-based/1/267691.html\|accessdate=19 April 2020}}</ref>
			* In 2012, Natco Pharma obtained [[compulsory license]] to produce a cheaper and generic version of [[Bayer]]'s anti-cancer medication [[Nexavar]].<ref name="ladder">{{cite news \|title=How Natco defied the odds to rise up India's pharma ladder \|url=https://www.moneycontrol.com/news/business/companies/how-natco-defied-the-odds-to-rise-up-indias-pharma-ladder-2583413.html \|accessdate=19 April 2020 \|work=Moneycontrol}}</ref>
			* In the United States, it launched [[influenza]] medication [[Tamiflu]] with marketing partner [[Alvogen]], [[multiple sclerosis]] treatment drug [[glatiramer acetate]] in partnership with [[Mylan]], and [[hepatitis C]] drugs under a licensing agreement with [[Gilead Sciences]].<ref name="niche" />
			* In 2015, Natco Pharma started production of [[Sofosbuvir]] in Nepal.<ref>{{Cite web\|title=Natco Pharma History {{!}} Natco Pharma Information\|url=https://economictimes.indiatimes.com/natco-pharma-ltd/infocompanyhistory/companyid-8305.cms\|access-date=2022-02-03\|website=The Economic Times\|language=en}}</ref>
			* In 2016, Natco Pharma launched the first [[Tamiflu]] capsule in the US market.<ref>{{Cite web\|title=Bayer cancer drug faces new Nexavar patent problems in India\|url=https://www.thepharmaletter.com/article/bayer-cancer-drug-faces-new-nexavar-patent-problems-in-india\|access-date=2022-02-03\|website=www.thepharmaletter.com}}</ref>
			* In 2017, Natco Pharma launched a generic version of [[blood cancer]] drug [[Pomalidomide]] at a 98% discount to the drug's selling price in the United States.<ref>{{cite news \|title=Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost \|url=https://www.firstpost.com/business/natco-pharma-launches-blood-cancer-drug-priced-rs-5000-20000-down-98-from-us-price-3436186.html \|accessdate=31 July 2020 \|work=Firstpost \|date=10 May 2017}}</ref>
			* In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in [[Nellore district]], [[Andhra Pradesh]].<ref>{{cite web \| url=https://www.dailyexcelsior.com/natco-pharma-to-invest-rs-100-cr-for-setting-up-agrichemical-facilities-in-andhra/ \| title=Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra \| date=25 January 2019 }}</ref>

	~~In 2003, Natco Pharma launched Veenat, a generic version of [[Novartis AG]]'s anti-cancer drug [[Glivec]]. It won the subsequent patent protection legal battle against Novartis in 2013.<ref name~~=~~niche/> In 2012, Natco Pharma obtained [[compulsory license]] to produce a cheaper and generic version of [[Bayer]]'s anti-cancer medication [[Nexavar]].<ref name~~=~~ladder>{{cite news \|title~~=~~How Natco defied the odds to rise up India's pharma ladder \|url~~=https://www.~~moneycontrol~~.~~com/news/business/companies/how-natco-defied-the-odds-to-rise-up-indias-pharma-ladder-2583413~~.~~html \|accessdate=19 April 2020 \|work=Moneycontrol}}</ref> In 2017, Natco Pharma launched a generic version of [[blood cancer]] drug [[Pomalidomide]] at a 98% discount to the drug's selling price~~ in the United States.<ref>{{cite news \|title=Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost \|url=https://www.firstpost.com/business/natco-pharma-launches-blood-cancer-drug-priced-rs-5000-20000-down-98-from-us-price-3436186.html \|accessdate=31 July 2020 \|work=Firstpost \|date=10 May 2017}}</~~ref>~~		== External links ==
			* [https://www.natcopharma.co.in/ Official website]
	In the United States, it launched [[influenza]] medication [[Tamiflu]] with marketing partner [[Alvogen]], [[multiple sclerosis]] treatment drug [[glatiramer acetate]] in partnership with [[Mylan]], and [[hepatitis C]] drugs under a licensing agreement with [[Gilead Sciences]].<ref name=niche>{{cite news \|title=Niche Play \|url=https://www.businesstoday.in/story/vc-nannapaneni-natco-pharma-ceo-best-ceo-business-today-survey-pharmaceutical-industry-hyderabad-based/1/267691.html \|accessdate=19 April 2020 \|work=Business Today}}</ref>

	==References==		==References==
Line 52:		Line 61:
	[[Category:1981 establishments in Andhra Pradesh]]		[[Category:1981 establishments in Andhra Pradesh]]
	[[Category:Indian companies established in 1981]]		[[Category:Indian companies established in 1981]]
			[[Category:Companies listed on the National Stock Exchange of India]]
			[[Category:Companies listed on the Bombay Stock Exchange]]
	{{India~~-company-stub}}~~
	~~{{corp-stub}}~~
	~~{{en-Wikipedia}}~~

CleanupBot: /* References */clean up, add source tag

2021-06-01T18:30:22Z

References: clean up, add source tag

← Older revision		Revision as of 00:00, 2 June 2021
Line 56:		Line 56:
	{{India-company-stub}}		{{India-company-stub}}
	{{corp-stub}}		{{corp-stub}}
			{{en-Wikipedia}}

>BrownHairedGirl: clean up

2021-04-08T05:05:56Z

clean up

New page

{{Infobox company
| name = Natco Pharma
| logo = Natco Pharma Logo.svg
| logo_size =
| caption =
| type = Public company
| genre =
| traded_as = {{NSE|NATCOPHARM}} <br /> {{BSE|524816}}
| predecessor =
| successor =
| foundation = 1981
| founders = VC Nannapaneni
| defunct =
| location_city = [[Hyderabad]]
| location_country = [[India]]
| locations =
| area_served = Global
| key_people = VC Nannapaneni (Chairman and MD)<ref>{{cite news |title=Facing headwinds in US, Natco Pharma looks to scale up business in China |url=https://www.livemint.com/companies/news/facing-headwinds-in-us-natco-pharma-looks-to-scale-up-business-in-china-1565511497326.html |accessdate=19 April 2020 |work=Livemint}}</ref><br />Rajeev Nannapaneni (CEO and Vice Chairman)<ref>{{cite news |title=Natco Pharma: In fine fettle |url=https://www.forbesindia.com/article/super-50-companies-2018/natco-pharma-in-fine-fettle/51067/1 |accessdate=19 April 2020 |work=Forbes India}}</ref>
| industry = [[Pharmaceuticals]]
| products =
| services =
| revenue =
| operating_income =
| net_income =
| aum =
| assets =
| equity =
| owner =
| num_employees =
| parent =
| divisions =
| homepage = [http://www.natcopharma.co.in natcopharma.co.in]
| footnotes =
}}

'''Natco Pharma''' is an Indian [[pharmaceutical]] company based in [[Hyderabad]], which makes finished dosage formulations and [[active pharmaceutical ingredients]]. It is the market leader in branded [[oncology]] medicines in India,<ref name=paraiv>{{cite news |title=Natco Pharma lines up 20 `Para IV' products |url=https://www.thehindubusinessline.com/companies/natco-pharma-lines-up-20-para-iv-products/article29408594.ece |accessdate=19 April 2020 |work=The Hindu Business Line}}</ref> and among the country's top three producers of [[hepatitis C]] drugs.<ref name=ladder/>

In 2003, Natco Pharma launched Veenat, a generic version of [[Novartis AG]]'s anti-cancer drug [[Glivec]]. It won the subsequent patent protection legal battle against Novartis in 2013.<ref name=niche/> In 2012, Natco Pharma obtained [[compulsory license]] to produce a cheaper and generic version of [[Bayer]]'s anti-cancer medication [[Nexavar]].<ref name=ladder>{{cite news |title=How Natco defied the odds to rise up India's pharma ladder |url=https://www.moneycontrol.com/news/business/companies/how-natco-defied-the-odds-to-rise-up-indias-pharma-ladder-2583413.html |accessdate=19 April 2020 |work=Moneycontrol}}</ref> In 2017, Natco Pharma launched a generic version of [[blood cancer]] drug [[Pomalidomide]] at a 98% discount to the drug's selling price in the United States.<ref>{{cite news |title=Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost |url=https://www.firstpost.com/business/natco-pharma-launches-blood-cancer-drug-priced-rs-5000-20000-down-98-from-us-price-3436186.html |accessdate=31 July 2020 |work=Firstpost |date=10 May 2017}}</ref>

In the United States, it launched [[influenza]] medication [[Tamiflu]] with marketing partner [[Alvogen]], [[multiple sclerosis]] treatment drug [[glatiramer acetate]] in partnership with [[Mylan]], and [[hepatitis C]] drugs under a licensing agreement with [[Gilead Sciences]].<ref name=niche>{{cite news |title=Niche Play |url=https://www.businesstoday.in/story/vc-nannapaneni-natco-pharma-ceo-best-ceo-business-today-survey-pharmaceutical-industry-hyderabad-based/1/267691.html |accessdate=19 April 2020 |work=Business Today}}</ref>

==References==
{{Reflist}}

{{Nifty 200 companies}}

{{Authority control}}

[[Category:Pharmaceutical companies of India]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:Pharmaceutical companies established in 1981]]
[[Category:1981 establishments in Andhra Pradesh]]
[[Category:Indian companies established in 1981]]

{{India-company-stub}}
{{corp-stub}}

Natco Pharma - Revision history

SabinaGuffey: revised

UpdateBot: robot: Update article (please report if you notice any mistake or error in this edit)

CleanupBot: /* References */clean up, add source tag

>BrownHairedGirl: clean up